Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

- Results show UVIDEM was well-tolerated with signs of durable disease control in advanced melanoma patients -

IRVINE, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today presented preliminary results from a Phase II UVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that UVIDEM was well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma.

The data were presented by Merrick I. Ross, M.D., Professor of Surgery, Chief, Melanoma Section, Department of Surgical Oncology at The University of Texas M. D. Anderson Cancer Center in Houston as an oral presentation titled "Clinical and immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi- institutional phase II clinical trial" (# 3004) at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago.

"We are in great need of new drugs to treat our patients with metastatic melanoma" said Dr. Ross. "The preliminary analysis of the phase II clinical trial with IDM Pharma's cancer vaccine, UVIDEM, suggests that several patients with advanced melanoma attained durable control of their disease after a treatment stimulating their own immune system cells. Additionally, the side effects experienced by our patients were minimal," he added.

Study design and findings

DC-MEL-202 is a single arm, two-stage Phase II trial designed to evaluate clinical and immunological activities and the safety of a multivalent dendritic cell-based vaccine in patients with in-transit or low volume metastatic melanoma. Thirty-three patients were treated in the study and the results to date are as follows:

    --  Clinical response (RECIST): out of 30 patients evaluable for efficacy,

        9 (30%) showed evidence of clinical benefit (1 complete re
'"/>




Page: 1 2 3 4 5 

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical
results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging
Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical
Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis
Treatment
Post Your Comments:
(Date:6/18/2013)... , June 18, 2013  Healthgrades, the leading ... and connect with physicians and hospitals, today issued ... in" When Making Healthcare Decisions to Get Your ... performing hospitals for maternity care, gynecologic surgery, as ... of women across 15 of the most common ...
(Date:6/18/2013)... 18, 2013  Pro football player and 2012 most ... family expert Jo Frost have potentially life-threatening ... the fully integrated specialty pharmaceutical business of Mylan Inc. ... this significant health problem. In recognition of the 25 ... Administration (FDA) approval of EpiPen ® (epinephrine) Auto-Injector, ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
Breaking Medicine Technology:Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
(Date:6/18/2013)... Healthcare Solutions , the parent ... today announced the appointment of Richard Leonardo to ... position, Leonardo will direct Healthcare Solutions’ national sales ... initiatives. , Recognized in the property and casualty ... more than 20 years of experience in business ...
(Date:6/18/2013)... New York, New York (PRWEB) June 18, 2013 ... forward in both state and federal court, a new report ... of more than 70,000 U.S. Food & Drug Administration (FDA) ... According to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena ... since 2008, while more than 1,300 have reportedly experienced uterine ...
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... likely to keep their scheduled medical appointments and ... physician listens, explains things clearly and knows them as ... research suggests. , "If people feel their doctor really ... doctor has their best interests at heart and may ... leader Tabor E. Flickinger, M.D., M.P.H., a fellow in ...
(Date:6/18/2013)... research scientist Daniel Perlman has discovered a way to ... foods that are consumed by humans, potentially opening the ... A U.S. patent (#8,460,738) on the new process and ... Phytosterols in plants and cholesterol molecules in animals are ... are attracted to one another. When they mix in ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Brandeis scientist invents anti-cholesterol process 2
... to identifying high-risk behaviors among adolescents. Injury risk, ... leading causes of adolescent morbidity and mortality; yet pediatricians ... concerns. That paradox of care is the motivation behind ... Pediatrics, which found adolescents who participated in computerized screening ...
... adults and is emerging in the world of pediatrics. A ... D insufficiency, causes rickets in children and can be treated ... as increased sun exposure. , A new study ... the first study to investigate vitamin D insufficiency in pediatric ...
... 1 Aflac Incorporated,announced today that Martin A. Durant ... chief financial officer. Susan R. Blanck has been,promoted to ... are,effective June 1, 2008., Durant first joined Aflac ... He was with Aflac for 10 years, eventually serving ...
... Prenatal biochemical screening tests are widely used to look ... serious handicap, or even death during gestation or in the ... able to detect fewer than half of the total chromosomal ... conference of the European Society of Human Genetics tomorrow (Monday ...
... of particular gene respond well to targeted therapy , , ... who have the normal version of a particular gene ... that includes adding the targeted therapy Erbitux to chemotherapy. ... normal, or "wild-type" form of the gene, according to ...
... melanoma tumors may make the cancer more vulnerable to chemotherapy, ... Duke Comprehensive Cancer Center. , We tested a compound that ... on the surface of a melanoma cell," said Douglas Tyler, ... Medical Center, and senior investigator on this study. "When chemotherapy ...
Cached Medicine News:Health News:Waiting room gadget may prove to be a life-saver 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 2Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Combination therapy packs 1-2 punch against melanoma 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: